The most common adverse events ( occurring in > @ % of patients ) were increased - glutamyltransferase ( @ -LSB- @ % -RSB- patients in the idalopirdine group vs two -LSB- @ % -RSB- in the placebo group ) , diarrhoea ( six -LSB- @ % -RSB- vs nine -LSB- @ % -RSB- ) , urinary tract infection ( three -LSB- @ % -RSB- vs nine -LSB- @ % -RSB- ) , fall ( three -LSB- @ % -RSB- vs eight -LSB- @ % -RSB- ) , increased alanine aminotransferase ( nine -LSB- @ % -RSB- vs none ) , and benign prostatic hyperplasia ( two -LSB- @ % -RSB- vs none ) .